TKIs Appear Safe in Patients With Chronic Myeloid Leukemia, CKD
the ONA take:
Tyrosine kinase inhibitors (TKIs) seem safe in patients with chronic myeloid leukemia (CML) in chronic-phase and chronic kidney disease, a recent study published online ahead of print in the journal Cancer has shown.
For the study, researchers investigated the incidence of acute injury and chronic kidney disease in 468 patients with newly diagnosed chronic-phase CML who were treated with imatinib, dasatinib, or nilotinib.
Results showed that 4% of patients experienced TKI-associated acute kidney injury. Researchers found that imatinib was associated with an increased incidence of acute kidney injury compared with dasatinib and nilotinib.
The study also demonstrated that 14% of patients developed chronic kidney disease while receiving TKI treatment. Of those, 84% were receiving imatinib. However, in patients with a history of chronic kidney disease, imatinib did not cause a significant decline in glomerular filtration rate.
"The administration of TKIs may be safe in the setting of CKD in CP CML patients, but close monitoring is still warranted," Musa Yilmaz, M.D., from the Baylor College of Medicine in Houston, TX, and colleagues wrote.
Tyrosine kinase inhibitors seem safe in patients with chronic myeloid leukemia in chronic-phase and chronic kidney disease.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer
- Clinical Trials May Benefit Oncology Patients
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|